XML 55 R46.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue Recognition from Collaboration and License Agreements - Additional Information (Details) - Collaboration and License Agreement - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | ---
Jun. 30, 2025 | Mar. 31, 2024 | May 31, 2020 | Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Feb. 29, 2024 | Dec. 31, 2023
Bristol-Myers Squibb Company |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue recognized |  |  |  | $ 0.3 | $ 0.0 | $ 0.3 | $ 2.6 |  |
Collaboration term expiration date |  |  | Nov. 30, 2023 |  |  |  |  |  |
Bristol-Myers Squibb Company | Undruggable targets |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue recognized |  | $ 2.6 |  |  |  |  |  |  |
Option fee payment |  | 0.1 |  |  |  |  |  |  |
Bristol-Myers Squibb Company | Druggable targets |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue recognized | $ 0.3 |  |  |  |  |  |  |  |
Bristol-Myers Squibb Company | Maximum |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments entitled to be received |  |  | $ 301.0 |  |  |  |  |  |
Bristol-Myers Squibb Company | Maximum | Research, Development and Regulatory Milestones |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments entitled to be received |  |  | 176.0 |  |  |  |  |  |
Bristol-Myers Squibb Company | Maximum | Commercial Milestones |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments entitled to be received |  |  | $ 125.0 |  |  |  |  |  |
Roche |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Milestones payments received |  |  |  |  |  |  |  | $ 40.0 |
Deferred revenue recognized |  |  |  | $ 0.0 | $ 1.1 | $ 0.0 | $ 50.9 |  |
Roche | Third Additional Clinical Development Plan |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue received |  | $ 4.0 |  |  |  |  |  |  |
Collaboration revenue receivable earned |  |  |  |  |  |  |  |  | $ 2.1

X
- Definition Amount of collaboration revenue receivable earned. + References No definition available. + Details
Name: | rptx_CollaborationRevenueReceivableEarned
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration Revenue received. + References No definition available. + Details
Name: | rptx_CollaborationRevenueReceived
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration term expiration date. + References No definition available. + Details
Name: | rptx_CollaborationTermExpirationDate
Namespace Prefix: | rptx_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestones payments received + References No definition available. + Details
Name: | rptx_MilestonesPaymentsReceived
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option fee. + References No definition available. + Details
Name: | rptx_OptionFee
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rptx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_UndruggableTargetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_DruggableTargetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_ResearchDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_ThirdAdditionalClinicalDevelopmentPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |